Back to Search Start Over

Advances in development of rechargeable mitochondrial antioxidants.

Authors :
Lukashev AN
Skulachev MV
Ostapenko V
Savchenko AY
Pavshintsev VV
Skulachev VP
Source :
Progress in molecular biology and translational science [Prog Mol Biol Transl Sci] 2014; Vol. 127, pp. 251-65.
Publication Year :
2014

Abstract

It has been about 15 years since the introduction of the rechargeable mitochondria-targeted antioxidants (RMA). Two major groups have been developing RMA of the MitoQ and SkQ types independently, and many additional trials have been done by other researchers. This has provided solid preclinical evidence of RMA efficacy in various models. Human trials of systemic MitoQ were not followed by further advances, but the safety of MitoQ and, most likely, other RMA in humans has been demonstrated. A prooxidant effect at higher concentrations of RMA was described. For RMA of the SkQ type, a large window between anti- and prooxidant concentrations was observed, which makes SkQs promising as potential medicines. Significant RMA-induced improvements in many diseases that do not have an accepted treatment have been described. This justifies further clinical trials of RMA.<br /> (© 2014 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1878-0814
Volume :
127
Database :
MEDLINE
Journal :
Progress in molecular biology and translational science
Publication Type :
Academic Journal
Accession number :
25149221
Full Text :
https://doi.org/10.1016/B978-0-12-394625-6.00010-6